BACKGROUND: The use of highly active antiretroviral therapy has significantly reduced morbidity and mortality, thus increasing life expectancy of human immunodeficiency virus (HIV)-infected individuals, transforming HIV into a chronic disease. Accordingly, there has been an increase in the number of comorbidities concomitantly present in these individuals and also an increased use of comedications, which may negatively impact antiretroviral therapy adherence. These factors can affect adherence to antiretroviral therapy. The role of the HIV clinical pharmacist is essential to achieve therapeutic objectives and enhance adherence.
METHODS:
We conducted a prospective observational study that included HIV-infected outpatients who attended the pharmaceutical care office of a hospital pharmacy service, which initiated antiretroviral treatment between January 2002, and December 2011. The variables analyzed in the study were demographics (sex and age), HIV transmission mode, and the following variables at the time of comedication collection: hepatitis C virus or hepatitis B virus coinfection, HIV plasma viral load (copies/mL) and CD4+ T-cell count (cells/µL), Centers for Disease Control and Prevention HIV classification, number of hospital admissions and emergency room visits, and antiretroviral therapy-related features (type at baseline, treatment-naïve status, and number of changes since starting antiretroviral therapy). For follow-up at 12 months, antiretroviral therapy adherence was measured through pharmacy dispensing records and the Morisky Medication Adherence Scale (MMAS). Patients were considered adherent if antiretroviral therapy adherence through dispensing records was > 90%, and the MMAS score was 4. Other variables were number of comorbidities and number of comedications for other chronic diseases (non-HIV drugs). According to the number of comorbidities, patients were categorized as having multiple chronic conditions (polypathology) if they had 2 or more chronic diseases. Polypharmacy was defined specifically as the use of 5 or more prescription medications in a medication regimen. In addition, a complexity therapeutic index of antiretroviral therapy was calculated for each patient. We determined the risk of drug-related problems using the tool Predictor Index. To identify independent predictors of adherence to antiretroviral therapy, we performed a univariate logistic regression. Afterward, those variables that showed statistical significance in the univariate analysis and those with P < 0.25 were included in a multivariate model. The sample size was estimated by the Freeman equation.
R E S E A R C H
• Several studies have identified demographic, clinical, and virologic features that can predict a lower adherence to antiretroviral therapy.
• Indicators of poor adherence to an antiretroviral regimen are a useful resource for pharmacists to help identify patients who are most in need of interventions to improve adherence. • Pharmacists are in an ideal position to improve adherence for patients with human immunodeficiency virus infection. The coordinated care between pharmacist and physicians improves patient-care outcomes.
What is already known about this subject
• Polypharmacy was identified as a predictor of nonadherence to antiretroviral therapy.
• Transmission risk by intravenous drug use, previous treatment with antiretroviral therapy, and high risk of drug-related problems are also associated with lower adherence. These facts support the key role that the pharmacist can play in adherence monitoring. patients, such as complementary and alternative medicines, 19, 20 psychiatric medications, 21 and other prescription drugs such as opioids. 22 In addition, the use of marijuana and other recreational drugs has been assessed. 21, 23, 24 The purpose of the current study was to determine the influence of comorbidities and comedications on ART adherence in HIV-infected patients.
What this study adds

■■ Methods
We conducted a prospective observational study that included HIV-infected outpatients who attended the pharmaceutical care office of a hospital pharmacy service, initiating antiretroviral treatment between January 2002, and December 2011. We excluded patients enrolled in clinical trials, those with psychiatric disorders that may affect treatment adherence, and those whose data were not available.
The follow-up period was 1 year (between January and December 2012). The variables analyzed in the study were demographics (sex and age), HIV transmission mode, and the following variables at the time of comedication collection: hepatitis C virus (HCV) or hepatitis B virus (HBV) coinfection, HIV plasma viral load (copies/milliliter [mL]) and CD4+ T-cell count (cells/microliter), Centers for Disease Control and Prevention (CDC) HIV classification, 25 and number of hospital admissions and emergency room visits. These variables were obtained by consulting analytics, microbiology reports, and the medical history of each patient.
Antiretroviral treatment-related features were also collected, obtained from a pharmacy dispensing program for outpatients (type of ART at baseline, treatment-naïve status, number of ART changes since beginning ART). Type of ART was classified as (a) 2 nucleoside reverse transcriptase inhibitors (NRTI) plus 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), (b) 2 NRTI plus 1 protease inhibitor (PI) ritonavir-boosted, and (c) others. For follow-up at 12 months, ART adherence was measured through pharmacy dispensing records and the Morisky Medication Adherence Scale (MMAS). 26 ART adherence through dispensing records was calculated as number of medications dispensed/number of medications prescribed, multiplied by 100, over a 1-year period. 27 MMAS is a questionnaire with 4 items that has been particularly useful in chronic conditions. The scale is scored 1 point for each "no" and 0 points for each "yes." The total score ranges from 0-3 (nonadherent) to 4 (adherent). The adherence questionnaire was carried out in successive visits to the pharmaceutical care office. Patients were considered adherent if ART adherence through dispensing records was > 90%, and the MMAS score was 4.
We obtained the number of comorbidities and comedications for other chronic diseases (non-HIV drugs) from review of the medical history and prescription drug history of each patient. According to the number of comorbidities, patients were categorized as having multiple chronic conditions (polypathology) if they had 2 or more chronic diseases. 28 Chronic conditions T he use of highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality, thus improving quality of life and increasing life expectancy of human immunodeficiency virus (HIV)-infected individuals. [1] [2] [3] [4] The emergence of new therapeutic strategies has converted HIV infection from a potentially fatal sickness into a chronic disease. 5 As a consequence, we can observe a progressive aging of the HIV-infected population. 6 Researchers estimate that by the year 2015, 50% of HIV-infected patients will be more than 50 years of age, and this percentage is expected to increase with time. 7 Because of this change, there has been an increase in the number of comorbid conditions concomitantly present in these individuals, as well as an increased use of comedications. 8 Recent data from the Swiss HIV Cohort demonstrated that 68% of patients had a comedication. 9 Polypharmacy, defined as ≥ 5 medications, is common among HIV-infected patients. Among patients ≥ 50 years of age from the Veterans Aging Cohort Study, 55% were using 5 or more daily medications. 10 The increased incidence of comorbidities in the aging HIVpositive population demands close monitoring and a keen awareness of the interplay between various therapies. The need for life-long therapy also necessitates high antiretroviral therapy (ART) adherence and long-term follow-up. Harms of polypharmacy include increased adverse drug events, geriatric syndromes (falls, fractures, and cognitive decline), and mortality. 10 We can prevent these harms with tools such as the Predictor Index, published by Morillo et al. (2012) . 11 This tool is a model for HIV patients that allows detection of the risk of drug-related problems (DRP) such as side effects.
In addition, polypharmacy may decrease medication adherence. 10 Complexity is one of the main causes of nonadherence. Currently, the complexity of the antiretroviral regimen has decreased, but HIV patients also have a greater number of prescription drugs for other chronic diseases. Thus, many HIV patients are characterized by multiple comorbid conditions and medical complexity, which may limit adherence and therapeutic success. Therefore, the role of pharmacists and other health care practitioners is important to achieve therapeutic objectives and enhance adherence. 12 In this connection, Martin et al. (2007) developed a method for quantifying antiretroviral regimen complexity for HIV patients. 13 That method is the first step toward obtaining a better understanding of how the complexity of HAART regimens affects adherence and medical outcomes. Subsequently, Libby et al. (2013) developed a medication regimen complexity index to estimate complexity for whole pharmacotherapy (HIV and non-HIV drugs). 14 Although the impact of regimen complexity, number of agents, and pill burden on medication adherence have been addressed in literature, most studies have focused on antiretroviral use and have failed to consider the impact of other medications or therapies. [15] [16] [17] [18] A few recent studies have considered the use of specific classes of medications on HIV-infected were classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification. Polypharmacy was defined specifically as the use of 5 or more prescription medications in a regimen, since this threshold is supported by empiric work. 10, 29 We included all non-HIV medication formulations to treat a chronic disease. Combination medications were handled as a unique medication. Otherwise, medications from the same group were treated independently.
In addition, a complexity therapeutic index of ART was calculated for each patient through the application available in Spanish at http://www.farmaciavalmecpv.com/consulta/actividad/indice-de-complejidad/. 30 This application is an adaptation created by Martin et al. 13 The index includes the number of pills per day, the dosing schedule, dosage form, and specific instructions associated with taking drugs.
To determine the risk of DRP, we used the Predictor Index developed by Morillo et al. 11 This index takes into account the need for dose adjustment in renal or liver impairment and the number of associated non-HIV medications. The tool allows researchers to place patients into 2 categories, high risk or low risk for developing DRP as medication side effects. The Predictor Index is available at http://estudiopredictor.sefh.es/ index.html.
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Statistical Analysis
For this study, we carried out a descriptive analysis. Quantitative variables were summarized with medians and interquartile ranges (IQR = quartiles 25 and 75). Qualitative variables were characterized with frequencies and percentages. To identify independent predictors of adherence to ART, we performed a univariate logistic regression. We also analyzed the collinearity between the variables. Subsequently, variables that showed statistical significance in the univariate analysis and those with P < 0.25 were included in a multivariate model. A 95% confidence interval (CI) was used. Validity of the model was evaluated by the Hosmer and Lemeshow test. The sample size was estimated by the Freeman equation 10 × (k + 1). Data analysis was performed using the statistical package SPSS 20.0 for Windows (IBM Corp., Armonk, NY).
■■ Results
We included 594 patients in the study, with baseline and clinical characteristics detailed in Table 1 . We excluded 25 patients either because data were not available (n = 12); patients were enrolled in clinical trials (n = 8); or patients had psychiatric disorders (n = 5). Most patients were men, and the median age was 47 years. Intravenous drug use (IDU = 61.4%) was 
AIDS = acquired immunodeficiency syndrome; ART = antiretroviral therapy; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IQR = interquartile range; mL = milliliter; mm 3 = cubic millimeter; NNRTI = non-nucleoside reverse transcriptase inhibitors; NRTI = nucleoside reverse transcriptase inhibitors; PI = protease inhibitor.
TABLE 2
Chronic Comorbidities of Study Patients
the main mode of HIV transmission. The proportion of HCVcoinfected patients was high (66.2%). In contrast, the percentage of patients with HBV was low (7.7%). The majority had an undetectable viral load (69.4%) and were diagnosed with CDC HIV classification (62.0%). The percentage of patients hospitalized (8.1%) was lower than the percentage of patients with ≥ 1 hospital emergency room visit (53.2%).
Regarding treatment-related characteristics, 76.1% of patients were naïve to ART, and we found 75% of patients were adherent to ART. We did not find adherence differences between the 2 methods for measuring ART adherence (MMAS and dispensing records). The risk of developing DRP was high in 32.0% of patients. The type of ART regimen was mainly NNRTI-based (39.2%), and one-third of patients were receiving a PI-based regimen. The median of comedications was 1.8 (IQR = 1-3). The number of comedications was high in nonadherent patients (5 [IQR = 4.5-6] vs. 2 [IQR = 1-3]). The majority of patients were classified as polypathological (72.6%), and 21.5% had polypharmacy. There were different comorbidities (Table 2) , although the most prevalent diseases were hyperlipidemia (18.9%), ischemic heart disease (18.5%), and hypertension (12.1%).
To identify predictors of ART adherence, Table 3 shows the variables included in the univariate analysis. Sex and age did not differ substantially between adherent and nonadherent HIV patients. There was a statistically significant relationship in the HIV transmission mode between adherent and nonadherent patients. Sexual transmission mode was more frequent in adherent, while IDU was more frequent in nonadherent patients. ART-naïve treatment was associated with better adherence (P < 0.001). Regarding clinical response, an undetectable viral load (< 20 copies/mL) and higher levels of CD4+ T-cell counts (74.5% vs. 58.0%, P < 0.001) were more frequent in adherent patients. Other variables, such as AIDSdefining condition (73.7% vs. 58.1%, P = 0.001) and hospital admissions (14.0% vs. 6.1%, P = 0.003), were significantly more prevalent in nonadherent patients than in adherent patients. ART adherence was also influenced by the type of antiretroviral regimen, so patients who were taking NNRTI-based therapies presented better adherence levels (31.3% vs. 41.9%, P = 0.010) than patients taking PI-based therapies (41.3% vs. 31.1%, P = 0.216). The percentage of nonadherent polypathological patients was significantly higher than the percentage of adherent polypathological patients (86.0% vs. 68.0%, respectively; P < 0.001). Regarding polypharmacy, the percentage of 
TABLE 3
Univariate Analysis of Variables Associated with Adherence nonadherent patients was significantly higher than the percentage of adherent patients (49.3% vs. 23.2%, respectively; P < 0.001). The complexity therapeutic index was higher in patients nonadherent to ART than in adherent patients (4.8 vs. 4.4, respectively), although it did not research statistical significance (P = 0.054). Multicollinearity was assessed but not found to be an issue between type of ART and the complexity index. The percentage of patients with high risk of DRP was significantly higher in nonadherent patients than in adherent (62.7% vs. 21.6%, respectively; P < 0.001).
Subsequently, multivariate analysis showed that HIV transmission risk by IDU, ART-nonnaïve status, non-ART changes, high risk of DRP, and polypharmacy were the independent predictors of nonadherence to ART (Table 4 ). This table includes the odds ratio for adherence. The value of the Hosmer and Lemeshow test confirmed the validity of this model (P = 0.378).
■■ Discussion
In our study, we found that polypharmacy is a predictor of nonadherence to ART among HIV-infected patients. Therefore, comedications can impair adherence, leading to worse treatment outcomes.
Several studies have examined the impact of polypharmacy on medication adherence. 32, 33 In the study carried out by Choudhry et al. (2011) , the researchers concluded that greater prescribing and filling complexity was associated with lower levels of adherence in patients with cardiovascular disease. 32 In a recent systematic review, nonadherence was associated with polypharmacy when focusing on the results of higher-quality studies. 34, 35 To date, all studies have shown that polypharmacy is robustly associated with nonadherence, but no study has focused on the HIV population. Nonadherence to ART is especially concerning, since it is associated with reduced effectiveness in viral suppression, allows viral resistance, and increases the risk of opportunistic diseases. 36 Ekwunife et al. (2012) have revealed that complementary and alternative medicine use could lower adherence to antiretroviral therapy. 19 Several authors have shown that taking fewer ART pills was independently associated with higher adherence. 15, 17, 37 Adherence and medication regimen complexity are closely linked, since adherence can be compromised by a high complexity of the treatment. However, researchers did not study the impact of comedications on ART adherence.
To date, no study has been conducted to evaluate the influence of the number of comorbidities in the adherence to ART. In our study, this variable was not related to adherence. However, in the study carried out by Maiese et al. (2012) , researchers found a relationship between the increasing number of comorbidities and discontinuation of ART. 38 Other authors have reported that specific diseases can affect adherence to ART, such as metabolic complications of HIV infection or bipolar disorder. 39, 40 In relation to the other variables analyzed in the multivariate analysis, we found that HIV transmission risk by IDU was an independent predictor of nonadherence to ART. Substance use is also associated with nonadherence. 41 In the same way, alcohol consumption demonstrates a relationship to poor adherence. 42 On the other hand, our study showed a significant relationship between adherence and being ART naïve. At present, there is limited evidence on adherence in ART naïve HIV patients. A study in a cohort of newly diagnosed HIV patients showed that for ART-naïve patients, once daily dosing of ART resulted in higher adherence than twice daily dosing. 43 Nevertheless, no studies have compared the adherence between naïve and non-naïve patients.
Further, we found that the high risk of DRP is an independent predictor of nonadherence. For this conclusion, we used the Predictor Index tool. 11 The influence of DRP on adherence to ART has not previously been evaluated.
Limitations
Our study has some limitations. It is commonly accepted that there is no gold standard for measuring medication adherence. 35 Pharmacy dispensing records and the MMAS are chosen because both are practical and inexpensive; they provide quantitative and qualitative data; and they are used in clinical practice and adherence research. However, both can overestimate adherence. Data from patients with low adherence are reliable, but it is not possible to ensure that patients with perfect dispensing records are taking the medication. In relation to self-reported measures such as MMAS, there is the potential for social desirability bias (i.e., patients may report what they think the clinician wants to hear and not their true medication-taking behavior). Self-reported measures, however, can help understand the reasons for nonadherence, compared with impersonal measures such as pharmacy records. To resolve this limitation, ART adherence is measured by a combination of 2 different methods, as recommended by the 44 On the other hand, we believe that when taken together with the size of our sample, the data provide strong evidence. Moreover, adherence overestimation should be equivalent in patients with < 90% and ≥ 90% adherence.
In relation to comedication, we have not included self-prescribed, herbal, and recreational drugs because these data were not available on all patients. We have not evaluated the adherence of comedications, which was not an objective in our study.
We also have not studied some factors that have been previously described as having an effect on adherence, such as mental illness, cognitive status, housing/food security, or social support because these factors could interfere with the comedications and comorbidities. That is, if a patient has a mental illness, that patient probably has poor adherence, independently of the number of comedications.
With the ever-increasing number of older patients, future research will be instrumental in addressing and improving adherence to comedications. In this sense, pharmacists are uniquely positioned to help patients manage their medications and provide adherence support. Additional training on developing relationships may further the role of pharmacists in supporting adherence. 45 Future research should define frailty and other age-associated events with enough specificity to provide early, easily attainable indices to allow the identification of frailty precursors in HIV-infected patients. A systematic review provides evidence that, with the growing number of HIV-positive individuals worldwide, the increasing complexity of HIV treatment, and the shortage of physicians in resourcelimited settings, clinical pharmacists trained in HIV pharmacotherapy are invaluable resources and are essential members of the HIV multidisciplinary care team.
